Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 59 (2), 372-6

Allogeneic Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease

Affiliations
Review

Allogeneic Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease

Franco Locatelli et al. Pediatr Blood Cancer.

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the only curative treatment for sickle cell disease (SCD), being successful in around 85-90% of patients. Mortality and long-term morbidity (including infertility, gonadal failure, and chronic graft-vs.-host disease) associated with conventional approaches curtail the number of patients who undergo allo-HSCT. Recently, it has been demonstrated that cord blood is as effective as and possibly safer than bone marrow in pediatric patients with SCD. Likewise, transplant strategies based on the use of reduced-intensity regimens and the induction of mixed chimerism have been explored to decrease allo-HSCT short- and long-term complications.

Similar articles

See all similar articles

Cited by 9 PubMed Central articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback